We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Reporting Research Misconduct in the Medical Literature

Robert Steinbrook, MD1; Rita F. Redberg, MD, MSc2
[+] Author Affiliations
1Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut
2Department of Medicine, University of California, San Francisco
JAMA Intern Med. 2015;175(4):492-493. doi:10.1001/jamainternmed.2014.8052.
Text Size: A A A
Published online


In this issue of JAMA Internal Medicine, we publish a report1 that highlights an important area for improved public reporting of clinical trials and enhanced transparency at the US Food and Drug Administration (FDA). Seife1 identifies numerous instances in which the FDA found evidence of apparent research misconduct serious enough to warrant regulatory action at clinical trial sites, but mention of these problems was largely missing from articles in medical journals. The specific examples cited by Seife1 are disturbing: a foot amputation 2 weeks after a stem cell procedure, although the published trial states that all patients were aware of “major clinical improvements in the treated (more ischemic) leg”; an entire study deemed unreliable by the FDA but published without mention of the issue; a falsification of documents in a number of trials, in part because the falsifications led to the death of a subject in a chemotherapy trial (the researcher pled guilty to fraud and criminally negligent homicide); and a claim of a mortality benefit for a drug that included data from a trial site where patient records were allegedly altered.

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles